Navigation Links
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Date:8/5/2008

The most common moderate/severe related adverse events in the once-daily and twice-daily groups respectively were: diarrhea (17 percent versus 15 percent), nausea (seven percent versus five percent), vomiting (three percent versus four percent), and increased triglycerides (two percent in both groups). There was no statistical difference between the groups.

-- At week 48, the overall impact of Kaletra, dosed once-daily or twice-daily, on grade 3-4 lab abnormalities, including cholesterol and triglycerides, the liver enzymes, SGOT/AST, and creatinine clearance was similar.

-- At week 48, there was a statistically significant difference in the increase of total cholesterol between the once-daily and twice-daily group.

About Abbott's Commitment to Fighting HIV/AIDS

HIV/AIDS is a global problem that demands shared commitment and shared responsibility. Abbott is committed to working with governments, multilateral organizations, nongovernmental organizations and patient groups to expand access to HIV treatments around the world. Abbott has also made significant investments in expanding manufacturing capacity to meet the growing demand for HIV treatment in developing countries.

Abbott's lopinavir/ritonavir formulations are among the lowest-priced protease inhibitors in the developing world. Abbott has been providing its HIV medicines at a price of US$500 per adult patient per year in all African and least developed countries since 2002, making these medicines more affordable than any generic copies.

Abbott and the company's philanthropic foundation, Abbott Fund, have invested more than US$100 million in the fight against HIV/AIDS in Africa and the developing world. Abbott Fund-supported programs have served more than 700,000 children and families. In addition, more than 250,000 patients have been tested through Abbott Fund-supported voluntary counseling and testing programs, with thousands being referred to treatment programs. Abb
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
3. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
4. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
5. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
7. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
8. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
9. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- Market Research Report on Global and ... professional and in-depth market survey on Global ... report firstly reviews the basic information of X-Ray ... technology. The report then explores global and China,s ... product specification, capacity, Production value, and market share ...
(Date:8/29/2014)... 2014  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), ... support services for the lawfully organized cannabis industry, ... approved the Company,s name and symbol change request. ... be known as Chuma Holdings, Inc. ... merger with the Company,s wholly-owned subsidiary, Chuma Holdings, ...
Breaking Medicine Technology:Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3
... Open-label Extension of Phase II Study Demonstrates ... Mass., June 12, 2007 /PRNewswire-FirstCall/ --,Indevus Pharmaceuticals, ... Phase II EXPRESS trial for pagoclone in ... the 47th annual,meeting of the New Clinical ...
... activity reported against CTCL, PTCL and Ovarian ... -- CuraGen,Corporation , a clinical-stage biopharmaceutical company ... the clinical development,program for belinostat, a histone ... clinical activity of belinostat,against cutaneous T-cell lymphoma ...
Cached Medicine Technology:Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 2Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 3Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 4Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 5Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 7Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 8Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 9CuraGen Presents Update on Clinical Development Program for,Belinostat 2CuraGen Presents Update on Clinical Development Program for,Belinostat 3CuraGen Presents Update on Clinical Development Program for,Belinostat 4CuraGen Presents Update on Clinical Development Program for,Belinostat 5CuraGen Presents Update on Clinical Development Program for,Belinostat 6CuraGen Presents Update on Clinical Development Program for,Belinostat 7CuraGen Presents Update on Clinical Development Program for,Belinostat 8
(Date:8/30/2014)... 2014 The establishment and creation ... been one of the main strategies of the ... positive impact around the world. , Architecturally stellar ... trained executives and trainers deliver L. Ron Hubbard's ... Vital statistics demonstrate that significant reduction in crime, ...
(Date:8/30/2014)... 30, 2014 After offering hyperbaric ... for the past several years, Dr. Roy Schmidt ... have announced a scholarship program for veterans who ... a meeting held this summer to discuss veterans’ ... reporters have shed light on the large number ...
(Date:8/30/2014)... 2014 Acne is a common problem millions of ... nothing more than a daily nuisance, for some, it can have ... acne can even lead to dramatic mood swings and depression. ... to clear up their skin. In some cases, that can make ... trial and error, those on a quest for clearer skin can ...
(Date:8/30/2014)... 2014 Market Research Report on ... a professional and in-depth market survey on Global ... reviews the basic information of Cell Disruptor including ... then explores global and China’s top manufacturers of ... value, and market share etc. The report further ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all things senior, ... Disease, Dementia, and Memory Loss . , Country singer Glen ... with the Alzheimer’s, inspired Seniors Guide writers to review the ... movie, out on October 14, 2014, shows a glimpse of ... disease – which inspires a final tour from the musician ...
Breaking Medicine News(10 mins):Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2
... As the most trusted and,accessible health care ... health and make more than 80 million recommendations ... will follow these,recommendations. In fact, a recent survey, ... Patient Information and Education, found that,most Americans (80%) ...
... Commonly Prescribed Generic Drugs will be priced at $4 for a ... 30-day supply and $10 for a 90-day supply, ... its Stater Bros. Super Rx Pharmacy locations will begin,offering generic drugs ... the most commonly prescribed generic drugs will now be,available for the ...
... half had experienced it before or during college, survey ... between partners, friends and acquaintances is common before and ... 910 undergraduates aged 17 to 22 (57.1 percent female) ... , Among the findings: , , 407 (44.7 ...
... Inc.,(Nasdaq: THRM ), a leader in non-invasive ... it will present at the Collins Stewart LLC,Fourth ... in New York,City. Stephen J. Fanning, Chairman, President ... Officer, will review the Company,s,business strategy, historical financial ...
... In a New York City metro-area first, a 93-year-old ... at NewYork-Presbyterian Hospital, the only center on the Eastern ... new stent graft was implanted under an FDA-approved clinical ... a complex form of abdominal aortic aneurysms in which ...
... Seventh Annual Joint Conference With Centro Medical Paitilla to Focus on ... ... of physicians from Cleveland,Clinic will travel to Panama in mid July to ... Meeting. The,subject of this year,s conference is the Central Nervous System: Benign ...
Cached Medicine News:Health News:Stater Bros. Super Rx Pharmacy(SM) Now Offering $4 Generic Prescription Drugs 2Health News:Relationship Violence Common Among College Students 2Health News:NYC first: Complex aneurysm treated using new fenestrated endograft stent 2Health News:Cleveland Clinic Physicians to Present at Medical Conference in Panama, July 11-12 2Health News:Cleveland Clinic Physicians to Present at Medical Conference in Panama, July 11-12 3
... resistance of stainless steel with the ... offers an electro-polished copper-alloy-stainless interior that ... sterile environment promotes the integrity of ... safety of laboratory staff. This exclusive ...
DH Autoflow Single Chamber Stackable Air-Jacketed CO2 Incubator...
US Autoflow Single Chamber Stackable Water-Jacketed CO2 Inc.w/ Humidity Display and Control...
... from commonly used protein expression procedures using ... medium, contains two media, EXPANSION BROTH (EB) ... E. coli cells are grown in EB, ... is almost completely repressed. For high level ...
Medicine Products: